Neuropsychological outcomes across the day in children with attention-deficit/hyperactivity disorder treated with atomoxetine: Results from a placebo-controlled study using a computer-based continuous performance test combined with an infra-red motion-tracking device

Journal of Child and Adolescent Psychopharmacology

Volumn 21, Issue 5, 2011, Pages 433-444

  Wehmeier, Peter M ^a   Schacht, Alexander ^b   Wolff, Christian ^c   Otto, Walter R ^d   Dittmann, Ralf W ^a   Banaschewski, Tobias ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b LILLY DEUTSCHLAND GMBH   (Germany)

^c Private Practice   (Germany)

^d Private Dental Practice   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; PLACEBO;

ABDOMINAL PAIN; AGGRESSION; ARTICLE; ATTENTION DEFICIT DISORDER; ATTENTION DISTURBANCE; CHILD; CHILD BEHAVIOR; CIRCADIAN RHYTHM; CLINICAL EVALUATION; COMPUTER ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXECUTIVE FUNCTION; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERACTIVITY; IMPULSIVENESS; MAJOR CLINICAL STUDY; MALE; MOTION ANALYSIS SYSTEM; MULTICENTER STUDY; NAUSEA; PAIN; PERFORMANCE MEASUREMENT SYSTEM; PHALANGOLARYNGEAL PAIN; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; REACTION TIME; SCHOOL CHILD; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; UPPER RESPIRATORY TRACT INFECTION;

ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DIAGNOSIS, COMPUTER-ASSISTED; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PLACEBOS; PROPYLAMINES;

EID: 80155129904     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2010.0142     Document Type: Article

References (52)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000.
2. Arnsten AF: Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: An important role for prefrontal cortex dysfunction. CNS Drugs 23(Suppl 1):33-41, 2009.
3. Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherton P, Buitelaar J, Danckaerts M, Döpfner M, Faraone SV, Rothenberger A, Sergeant J, Steinhausen HC, Sonuga-Barke EJS, Taylor E: Longacting medications for the hyperkinetic disorders. A systematic review and European treatment guidelines. Eur Child Adolesc Psychiatry 15:476-495, 2006.
4. Banaschewski T, Roessner V, Dittmann RW, Santosh PJ, Rothenberger A: Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry 13(Suppl 1):I102-I116, 2004.
5. Barkley, RA: The ecological validity of laboratory and analogue assessment methods of ADHD symptoms. J Abnorm Child Psychol 19:149-178, 1991.
6. Biederman J, Faraone SV: Attention-deficit hyperactivity disorder. Lancet 366:237-248, 2005.
7. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharm Ther 69:89-95, 2001.
8. Carlson GA, Dunn D, Kelsey D, Ruff D, Ball S, Ahrbecker L, Allen AJ: A pilot study for augmenting atomoxetine with methylphenidate: Safety of concomitant therapy in children with attentiondeficit/ hyperactivity disorder. Child Adolesc Psychiatry Ment Health 1:10, 2007.
9. Castellanos FX, Sonuga-Barke EJ, Scheres A, Di Martino A, Hyde C, Walters JR: Varieties of attention-deficit/hyperactivity disorderrelated intra-individual variability. Biol Psychiatry 57:1416-1423, 2005.
10. Cheng JY, Chen RY, Ko JS, Ng EM: Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta- analysis and meta-regression analysis. Psychopharmacology 194:197-209, 2007.
11. Coghill D, Soutullo C, d'Aubuisson C, Preuss U, Lindback T, Silverberg M, Buitelaar J: Impact of ADHD on the patient and family. Results from a European survey. Child Adolesc. Psychiatry Ment Health 2:31, 2008.
12. Crosbie J, Schachar R: Deficient inhibition as a marker for familial ADHD. Am J Psychiatry 158:1884-1890, 2001.
13. Denckla MB: Research on executive function in a neurodevelopmental context: Application of clinical measures. Dev Neurpsychol 12:5-15, 1996.
14. di Michele F, Princhep L, John ER, Chabot RJ: The neurophysiology of attention-deficit/hyperactivity disorder. Int J Psychophysiol 58:81-93, 2005.
15. Döpfner M, Gerber WD, Banaschewski T, Breuer D, Freisleder FJ, Gerber-von Müller G, Günter M, Hässler F, Ose C, Rothenberger A, Schmeck K, Sinzig J, Stadler C, Uebel H, Lehmkuhl G: Comparative efficacy of once-a-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting. Eur Child Adolesc Psychiatry 13(Suppl 1):I93-I101, 2004.
16. Döpfner M, Lehmkuhl G: DISYPS-KJ: Diagnostik-System für psychische Störungen im Kindes- und Jugendalter nach ICD-10 und DSM-IV. Second Edition. Bern, Switzerland: Hans Huber; 2000.
17. Doyle AE: Executive functions in attention-deficit/hyperactivity disorder. J Clin Psychiatry 67(Suppl 8):21-26, 2006.
18. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R: ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretations. NY: The Guilford Press; 1998; pp. 28-42.
19. Faedda GL, Teicher MH: Objective measures of activity and attention in the differential diagnosis of psychiatric disorders of childhood. Essent Psychopharmacol 6:239-249, 2005.
20. Faraone SV: Using meta-analysis to compare the efficacy of medications for attention-deficit/hyperactivity disorder in youths. PT 34:678-694, 2009.
21. Faries DE, Yalcin I, Harder D, Heiligenstein JH: Validation of the ADHD Rating Scale as a clinician administered and scored instrument. J Atten Disord 5:39-47, 2001.
22. Guy W: ECDEU Assessment Manual for Psychopharmacology. Vol. 338. Washington, DC: US Department of Health, Education and Welfare; 1976; pp.534-537.
23. Halperin JM, Wolf L, Greenblatt ER, Young JG: Subtype analysis of commission errors on the continuous performance test. Dev Neuropsychol 7:207-217, 1991.
24. Heiser P, Frey J, Smidt J, Sommerlad C, Wehmeier PM, Hebebrand J, Remschmidt H: Objective measurement of hyperactivity, impulsivity, and inattention in children with hyperkinetic disorders before and after treatment with methylphenidate. Eur Child Adolesc Psychiatry 13:100-104, 2004.
25. Heiser P, Heinzel-Gutenbrunner M, Frey J, Smidt J, Grabarkiewicz J, Friedel S, Kühnau W, Schmidtke J, Remschmidt H, Hebebrand J: Twin study on heritability of activity, attention, and impulsivity as assessed by objective measures. J Atten Disord 9:575-581, 2006.
26. Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, Sutton VK, Gonzales J, Malcolm SK, Schuh KJ, Allen AJ: Once-daily atomoxetine treatment for children with attentiondeficit/ hyperactivity disorder, including an assessment of evening and morning behavior: A double-blind, placebo-controlled trial. Pediatrics 114:e1-e8, 2004.
27. Kelsey D, Sutton V, Schuh K, Dell'Agnello G, Sumner C: Once-Daily Atomoxetine for ADHD: Update on Evening and Morning Behavior. Presented at the 13th International Congress of the European\ Society for Child and Adolescent Psychiatry (ESCAP), Florence, Italy, August 25-29, 2007.
28. Maziade M, Rouleau N, Lee B, Rogers A, Davis L, Dickson R: Atomoxetine and neuropsychological function in children with attention- deficit/ hyperactivity disorder: Results of a pilot study. J Child Adolesc Psychopharmacol 19:709-718, 2009.
29. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee FR, Sangal RB, Saylor K, West S, Kelsey D, Wernicke J, Trapp NJ, Harder D: Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study. Am J Psychiatry 159:1896-1901, 2002.
30. National Institutes of Mental Health (NIMH). Clinical global impressions. Psychopharmacol Bull 21:839-943, 1985.
31. Newcorn JH, Sutton VK, Zhang S, Wilens T, Kratochvil C, Emslie GJ, D'Souza DN, Schuh LM, Allen AJ: Characteristics of placebo responders in pediatric clinical trials of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 48:1165-1172, 2009.
32. Nigg JT, Willcutt EG, Doyle AE, Sonuga-Barke EJ: Causal heterogeneity in attention-deficit/hyperactivity disorder: Do we need neuropsychologically impaired subtypes? Biol Psychiatry 57:1224-1230, 2005.
33. Paulus MP, Geyer MA: A temporal and spatial scaling hypothesis for the behavioral effects of psychostimulants. Psychopharmacology 104: 6-16, 1991.
34. Polanczyk G, Silva de Lima M, Lessa Horta B, Biederman J, Rohde LA: The worldwide prevalence of ADHD: A systemtic review and metaregression analysis. Am J Psychiatry 164:942-948, 2007.
35. Riccio CA, Reynolds CR, Lowe P, Moore JJ: The continuous performance test: A window on the neural substrates for attention? Arch Clin Neuropsychol 17:235-272, 2002.
36. Rubia K, Overmeyer S, Taylor E, Brammer M, Williams SC, Simmons A, Bullmore ET: Hypofrontality in attention deficit hyperactivity disorder during higher-order motor control: A study with functional MRI. Am J Psychiatry 156:891-896, 1999.
37. Sonuga-Barke EJS, Swanson JM, Coghill D, DeCory HH, Hatch SJ: Efficacy of two once daily methylphenidate formulations compared across dose levels at different times of the day. Preliminary indications from a secondary analysis of the COMACS study data. BMC Psychiatry 4:28, 2004.
38. Salthouse TA: Attentional blocks are not responsible for age-related slowing. J Gerontol 48,263-270, 1993.
39. Sutton VK, Sumner C, Allen A, Feng W, Schuh K, Michelson D: Validity, reliability, and Responsiveness of the DPREMB-R Scale for ADHD. In: Scientific Proceedings of the 50th Anniversary Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP). Miami Beach, FL, October 14-19, 2003, pp. 169-170.
40. Svanborg P, Thernlund G, Gustafsson PA, Hägglöf B, Poole L, KadesjöB: Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: A randomized, double-blind, placebo-controlled study in stimulant-naïve Swedish children and adolescents. Eur Child Adolesc Psychiatry 18:240-249, 2009.
41. Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshey Dirksen SJ, Hatch SJ, the COMACS Study Group: Comparison of oncedaily extended release methylphenidate formulations in children with Attention-Deficit/Hyperactivity Disorder in the laboratory school (the COMACS study). Pediatrics 113:e206-e216, 2004.
42. Tabori-Kraft J, Sørensen MJ, Kaergaard M, Dalsgaard S, Thomsen PH: Is OPTAx useful for monitoring the effect of stimulants on hyperactivity and inattention? A brief report. Eur Child Adolesc Psychiatry 16:347-351, 2007.
43. Tannock R: Attention deficit hyperactivity disorder: Advances in cognitive, neurobiological, and genetic research. J Child Psychol Psychiatr 39,65-99, 1998.
44. Teicher MH: Actigraphy and motion analysis: New tools for psychiatry. Harv Rev Psychiatry 3:18-35, 1995.
45. Teicher MH, Anderson CM, Polcari A, Glod CA, Maas LC, Renshaw PF: Functional deficits in basal ganglia of children with attentiondeficit/ hyperactivity disorder shown with functional magnetic resonance imaging relaxometry. Nat Med 6:470-473, 2000.
46. Teicher MH, Ito Y, Glod CA, Barber NI: Objective measurement of hyperactivity and attentional problems in ADHD. J Am Acad Child Adolesc Psychiatry 35:334-342, 1996.
47. Teicher MH, Lowen SB, Polcari A, Foley M, McGreenery CE: Novel strategy for the analysis of CPT data provides new insight into the effects of methylphenidate on attentional states in children with ADHD.J Child Adolesc Psychopharmacol 14:219-232, 2004.
48. Teicher MH, Polcari A, Anderson CM, Andersen SL, Lowen SB, Navalta CP: Rate dependency revisited: Understanding the effects of methylphenidate in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 13:41-51, 2003.
49. Teicher MH, Polcari A, McGreenery CE: Utility of objective measures of activity and attention in the assessment of therapeutic response to stimulants in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 18:265-270, 2008.
50. Wehmeier PM, Dittmann RW, Schacht A, Helsberg K, Lehmkuhl G: Morning and evening behavior in children and adolescents treated with atomoxetine once daily for attention-deficit/hyperactivity disorder (ADHD): Findings from two 24-week, open-label studies. Child Adolesc Psychiatry Ment Health 3:5, 2009.
51. Wehmeier PM, Schacht A, Ulberstad F, Lehmann M, Schneider- Fresenius C, Lehmkuhl G, Dittmann RW, Banaschewski T: Does atomoxetine Improve executive function, inhibitory control, and hyperactivity? Results from a placebo-controlled trial using quantitative measurement technology. J Clin Psychopharmacol in press.
52. Wolraich ML, Greenhill LL, Pelham W, Swanson J, Wilens T, Palumbo D, Atkins M, McBurnett K, Bukstein O, August G: Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics 104:883-892, 2001.